25.96
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating - TipRanks
Janux Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - PrintWeekIndia
Why Intel Stock Is Plummeting Today - The Globe and Mail
What makes Janux Therapeutics Inc. stock attractive to long term investorsRapid-fire capital growth - jammulinksnews.com
Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating - TipRanks
Janux Therapeutics Faces Trade Policy Challenges: Impact on Operations and Growth - TipRanks
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics - TipRanks
What analysts say about Janux Therapeutics Inc. stockStrongest growth potential - PrintWeekIndia
Is Janux Therapeutics Inc. stock a growth or value playHigh-profit capital plays - jammulinksnews.com
What drives Janux Therapeutics Inc. stock priceOutstanding capital appreciation - Autocar Professional
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Business Wire
Top Stocks Powering the Fourth Industrial Revolution - The Globe and Mail
Is Janux Therapeutics Inc. a good long term investmentFree Predictions - Autocar Professional
Why RTX Stock Is Down Today - The Globe and Mail
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc. - TipRanks
Teacher Retirement System of Texas Sells 884 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Upgraded at Wall Street Zen - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $91.89 Consensus PT from Analysts - Defense World
E.W. Scripps (NASDAQ:SSP) Lowered to Sell Rating by Wall Street Zen - Defense World
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - BioSpace
Janux Therapeutics to Showcase New Preclinical Programs at Virtual R&D Day - AInvest
September 19th Options Now Available For Janux Therapeutics (JANX) - Nasdaq
How Janux Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser
Why Janux Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Janux Therapeutics Inc. stock price move sharplyProfessional Stock Screener - Newser
Raymond James Financial Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Argus Initiates Coverage on CoreWeave (NASDAQ:CRWV) - Defense World
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Raymond James initiates Janux Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target - MarketScreener
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):